Max Chat
Share chart Lupin Limited
Extended chart
Simple chart
About Lupin Limited
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.Main settings
ISIN
INE326A01037
Industry
Pharmaceuticals
Sector
Health Care
Валюта
inr
Валюта отчета
inr
Див.доход ао
0.2475
Дивиденд ао
8
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 3.73 | 5 |
| P/BV | 5.1 | 3 |
| P/E | 38.27 | 4 |
Efficiency
| Title | Value | Grade |
| ROA | 8.15 | 3 |
| ROE | 14.31 | 4 |
| ROIC | 3.63 | 1 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0.2475 | 0.63 |
| DSI | 0.9286 | 9.29 |
| Average dividend growth | 7.18 | 10 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | 2.37 | 6 |
| Debt/Ratio | 0.1846 | 10 |
| Debt/Equity | 0.6695 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 27.85 | 4 |
| Yield Ebitda, % | -34.8 | 0 |
| Yield EPS, % | -799.78 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 2 000.35 ₹ | 0 ₹ | 0 ₹ | 0 % | 0 % | 0 % |
| Week | 1 993.7 ₹ | 0 ₹ | 0 ₹ | 0.33 % | 0 % | 0 % |
| Month | 1 979.05 ₹ | 2 000.35 ₹ | 2 027.55 ₹ | 1.08 % | 0 % | 0 % |
| Three month | 1 921.3 ₹ | 1 935.8 ₹ | 2 107.7 ₹ | 4.11 % | 0 % | 0 % |
| Half a year | 2 186.65 ₹ | 1 891.45 ₹ | 2 199.55 ₹ | -8.52 % | 0 % | 0 % |
| Year | 2 172.2 ₹ | 1 786.4 ₹ | 2 396.3 ₹ | -7.91 % | 0 % | 0 % |
| 3 years | 662.25 ₹ | 627.25 ₹ | 2 396.3 ₹ | 202.05 % | 0 % | 0 % |
| 5 years | 844.6 ₹ | 590.3 ₹ | 2 396.3 ₹ | 136.84 % | 0 % | 0 % |
| 10 years | 547 ₹ | 547 ₹ | 2 396.3 ₹ | 365.69 % | 0 % | 0 % |
| Year to date | 2 067.75 ₹ | 1 891.45 ₹ | 2 396.3 ₹ | -3.26 % | 0 % | 0 % |
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Vinita D. Gupta | CEO & Executive Director | 109.2M | 1968 (57 years) |
| Mr. Nilesh Deshbandhu Gupta | MD & Executive Director | 49.6M | 1974 (51 year) |
| Mr. Ramesh Swaminathan | Global CFO, CRO, Head of Corporate Affairs & Executive Director | 66.86M | 1966 (59 years) |
| Mr. Christoph Funke | Chief Technical Operations Officer | ||
| Mr. Sreeji Gopinathan | Chief Information Officer | ||
| Dr. Shahin Fesharaki | Global Chief Scientific Officer | ||
| Mr. Ravi Agrawal | Sr. Vice President of Investor Relations and M&A | ||
| Dr. Sofia Mumtaz | President of Legal and Compliance of Australia, Japan & Canada Business | ||
| Mr. Amit Kumar Gupta | Company Secretary & Compliance Officer | ||
| Ms. Rajalakshmi Azariah | Vice President & Global Head of Corporate Communications |
About company
Address: India, Mumbai, Kalpataru Inspire - Open in google maps, Open in yandex maps
Website: https://www.lupin.com
Website: https://www.lupin.com
